Söndag 27 April | 10:08:34 Europe / Stockholm

Prenumeration

Kalender

Est. tid*
2025-10-23 08:00 Kvartalsrapport 2025-Q3
2025-07-15 08:00 Kvartalsrapport 2025-Q2
2025-05-28 N/A X-dag ordinarie utdelning BONEX 0.00 SEK
2025-05-27 N/A Årsstämma
2025-04-24 - Kvartalsrapport 2025-Q1
2025-02-25 - Bokslutskommuniké 2024
2024-10-24 - Kvartalsrapport 2024-Q3
2024-07-11 - Kvartalsrapport 2024-Q2
2024-05-17 - X-dag ordinarie utdelning BONEX 0.00 SEK
2024-05-16 - Årsstämma
2024-04-25 - Kvartalsrapport 2024-Q1
2024-02-15 - Bokslutskommuniké 2023
2023-10-26 - Kvartalsrapport 2023-Q3
2023-07-13 - Kvartalsrapport 2023-Q2
2023-05-19 - X-dag ordinarie utdelning BONEX 0.00 SEK
2023-05-17 - Årsstämma
2023-04-27 - Kvartalsrapport 2023-Q1
2023-02-16 - Bokslutskommuniké 2022
2022-10-27 - Kvartalsrapport 2022-Q3
2022-07-14 - Kvartalsrapport 2022-Q2
2022-05-20 - X-dag ordinarie utdelning BONEX 0.00 SEK
2022-05-19 - Årsstämma
2022-05-04 - Kvartalsrapport 2022-Q1
2022-02-17 - Bokslutskommuniké 2021
2021-11-04 - Kvartalsrapport 2021-Q3
2021-07-15 - Kvartalsrapport 2021-Q2
2021-05-21 - X-dag ordinarie utdelning BONEX 0.00 SEK
2021-05-20 - Årsstämma
2021-05-06 - Kvartalsrapport 2021-Q1
2021-02-17 - Bokslutskommuniké 2020
2020-11-05 - Kvartalsrapport 2020-Q3
2020-07-17 - Kvartalsrapport 2020-Q2
2020-05-20 - X-dag ordinarie utdelning BONEX 0.00 SEK
2020-05-19 - Årsstämma
2020-05-08 - Kvartalsrapport 2020-Q1
2020-02-26 - Bokslutskommuniké 2019
2019-11-07 - Kvartalsrapport 2019-Q3
2019-07-25 - Kvartalsrapport 2019-Q2
2019-05-15 - X-dag ordinarie utdelning BONEX 0.00 SEK
2019-05-14 - Årsstämma
2019-05-02 - Kvartalsrapport 2019-Q1
2019-02-27 - Bokslutskommuniké 2018
2018-11-07 - Kvartalsrapport 2018-Q3
2018-07-26 - Kvartalsrapport 2018-Q2
2018-05-23 - X-dag ordinarie utdelning BONEX 0.00 SEK
2018-05-22 - Årsstämma
2018-05-04 - Kvartalsrapport 2018-Q1
2018-02-20 - Bokslutskommuniké 2017
2017-11-02 - Kvartalsrapport 2017-Q3
2017-08-17 - Kvartalsrapport 2017-Q2

Beskrivning

LandSverige
ListaLarge Cap Stockholm
SektorHälsovård
IndustriMedicinteknik
Bonesupport är verksamt inom medicinteknikbranschen och fokuserar på utveckling och tillverkning av biokeramiska implantat för benreparation och rekonstruktion. Bolagets produkter riktar sig till kirurger och sjukvårdsinstitutioner. Verksamheten är global med en huvudsaklig närvaro i Europa, Nordamerika och Asien. Bonesupport grundades 1999 och har sitt huvudkontor i Lund.
2022-09-08 08:00:00

BONESUPPORT™, an emerging leader in orthobiologics for the management of bone injuries, today announces the publication of mid- to long-term data confirming the sustained clinical effectiveness of CERAMENT G in a single-stage protocol to manage chronic osteomyelitis.

The study followed 100 patients treated at the Nuffield Orthopaedic Centre, Oxford University Hospitals. Results at a mean follow-up of 6.05 years [range: 4.2 to 8.4 years] were reported:

  • 94% of patients remained infection-free
  • 3% fracture rate and no further pathologic fractures beyond the first year after surgery

“These results over a long follow-up period confirm that our protocol using CERAMENT G remains highly effective over several years. There are hardly any prospective studies on bone graft substitutes with a follow-up over two years. Additionally, we were able to achieve these results in single-stage operation due to CERAMENT G’s unique properties of eluting high concentrations of local antibiotics and providing bone remodeling. Reducing the number of surgical procedures is more patient-friendly and allows for a cost-effective strategy to tackle chronic osteomyelitis,” said Professor Martin McNally, lead author and lead consultant in limb reconstruction surgery at Oxford University Hospital.

The study was published in the September issue of The Bone and Joint Journal (see reference below). The long-term results will be presented, and has been selected as one of the ten best papers, at this year’s annual meeting of the European Bone and Joint Infection Society (EBJIS) held in Graz, Austria on 8-10 September. Approximately 500 surgeons are expected to attend.

“Professor McNally’s group show long-term results that have not been displayed with any other orthobiologics product. This study will be influential in transforming the standard of care,” said Emil Billbäck, CEO of BONESUPPORT.

CERAMENT G is implanted to promote bone healing in bone voids or defects and simultaneously to protect it from infection. More than 70,000 patients have been treated thus far using the CERAMENT bone healing technology.

Reference

McNally, M, et al., ‘Mid- to Long-Term Results of Single-Stage Surgery for Patients with Chronic Osteomyelitis Using a Bioabsorbable Gentamicin-Loaded Ceramic Carrier’, The Bone & Joint Journal, 104-B.9 (2022), 1095–1100 <https://doi.org/10.1302/0301-620X.104B9.BJJ-2022-0396.R1>